ProteanFect achieves high transfection efficiency with DNA/mRNA in Jurkat T cells
ProteanFect demonstrates superior transfection efficiency for both EGFP pDNA and mRNA in Jurkat T cells compared to Lipofectamine 3000 and MessengerMAX. It achieves significantly higher fluorescence intensity and frequency, underscoring its enhanced delivery capability and optimized expression performance in these challenging immune cells.
ProteanFect achieves high transfection efficiency of high molecular weight nucleic acids or co-transfection of multiple nucleic acids in Jurkat T cells
ProteanFect demonstrates robust transfection efficiency in K562 cells, as evidenced by a significant increase in EGFP-positive cells post-transfection, achieving a 50.7% expression rate. Additionally, it effectively mediates gene knockdown, with target-siRNA reducing gene expression by 64% at 24 hours and 72% at 48 hours, normalized to GAPDH.
ProteanFect achieves high transfection efficiency in K562 cells
ProteanFect demonstrates robust transfection efficiency in K562 cells, as evidenced by a significant increase in EGFP-positive cells post-transfection, achieving a 50.7% expression rate. Additionally, it effectively mediates gene knockdown, with target-siRNA reducing gene expression by 64% at 24 hours and 72% at 48 hours, normalized to GAPDH.